Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Telomere Associated Variables (TAVs) in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04124900
Recruitment Status : Recruiting
First Posted : October 14, 2019
Last Update Posted : October 30, 2019
Sponsor:
Information provided by (Responsible Party):
Life Length SL

Brief Summary:

This research project results from the interest in continuing the collaboration with the previous LL-HURS-ONC001 clinical validation study, which gives cause to the present study. LL-HURS-ONC001 was carried out with the participation of HURS' Principal Investigator and the team of experts in prostate cancer, as well as with the participation of the Sponsor's scientific and development team, Life Length SL, led by Dr. Najarro.

The main objective of this study is to demonstrate the efficacy of the PROSTAV test in cutting down on unnecessary biopsies in prostate cancer screening/early diagnosis. PROSTAV is a minimally invasive test, easy to implement as biomarker for prostate cancer diagnosis. The efficacy of the PROSTAV test is clinically validated by the results obtained in a previous study, LL-HURS-ONC001.

The purpose of this study is to advance in the development of new biomarkers in areas where there is a clinical need and where the telomeric profile influences medical decisions within the patient's clinical context. The association level between each individual's telomere biology and the results of the prostate biopsy will be confirmed. Data will be collected to subsequently delve deeper into and accurately establish the effect of this measure in prostate cancer patient management to substantiate its implementation in standard care.


Condition or disease
Prostate Cancer

  Show Detailed Description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 535 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement of Telomere Associated Variables (TAVs) for Diagnostic Purposes in Prostate Cancer
Actual Study Start Date : July 15, 2019
Estimated Primary Completion Date : November 15, 2020
Estimated Study Completion Date : November 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Group/Cohort
patients at prostate cancer risk diagnosed

The study is composed of one single subject cohort. After risk evaluation, prostate biopsies will be performed for diagnostic purposes on all recruited patients. The cases are sorted into two groups after diagnosis:

  • Group 1: patients at prostate cancer risk diagnosed with significant prostate cancer after prostatic biopsy (Gleason >6).
  • Group 2: patients at prostate cancer risk diagnosed free of cancer after prostate biopsy. There will be a subdivision within this group in patients without significant prostate cancer ( No cancer o Non-significant prostate cancer (Gleason ≤6)).



Primary Outcome Measures :
  1. Telomere Associated Variables [ Time Frame: One day single measurement ]
    This is a clinical multicenter study focused on evaluating the efficacy of the PROSTAV test in patients at risk of prostate cancer based on data of telomere associated variables (TAV) as risk-score. The study comprises one single prospective observational phase.


Biospecimen Retention:   Samples With DNA
PBMCs isolated from fresh blood samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Sampling Method:   Non-Probability Sample
Study Population

The study population will include cases with high PSA levels (PSA<10 ng/ml) and with indication criterion for prostate cancer biopsy based on prostate cancer risk-related endpoints.

The study is composed of one single subject cohort. After risk evaluation, prostate biopsies will be performed for diagnostic purposes on all recruited patients. The cases are sorted into two groups after diagnosis:

  • Group 1: patients at prostate cancer risk diagnosed with significant prostate cancer after prostatic biopsy (Gleason >6).
  • Group 2: patients at prostate cancer risk diagnosed free of cancer after prostate biopsy. There will be a subdivision within this group in patients without significant prostate cancer:

    • No cancer
    • Non-significant prostate cancer (Gleason ≤6).
Criteria

Inclusion Criteria:

  • To be over 18 years of age.
  • To have given written consent to participate in the study.
  • To be classified as a patient at prostate cancer risk according to criteria of high PSA levels (<10 ng/ml) and the urologist's decision to perform a prostate biopsy in standard of care.
  • To be diagnosed by a prostate biopsy with or without concomitant MRI.

Exclusion Criteria:

  • Patients who have undergone a previous biopsy.
  • Patients that have received Alpha-5 reductase therapy.
  • Existing serious active liver, lung or kidney disease, as well as severe active infections.
  • Existing serious disease or psychiatric disorder that prevents them from expressing informed consent and/or if patients are not able to follow protocol procedures and give their informed consent.
  • Patients at risk resulting from conventional blood extraction.
  • Subjects with active neoplasm diagnosed during the past five years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04124900


Contacts
Layout table for location contacts
Contact: Pilar Najarro +(34) 917378483 prostav@lifelength.com

Locations
Layout table for location information
United States, Texas
Houston Methodist Research Institute Not yet recruiting
Houston, Texas, United States, 77030
Contact: Vivian MacDonnell, CCRP    713-441-8113    vmmacdonnell@houstonmethodist.org   
Principal Investigator: Brian J Miles, MD         
Spain
University Hospital Reina Sofía Recruiting
Córdoba, Spain, 14004
Contact: María José Requena, MD    (+34) 957 011 057      
Contact: Enrique Gómez, MD    (+34) 957 011 057      
Principal Investigator: María José Requena, MD         
Principal Investigator: Enrique Gómez, MD         
Sponsors and Collaborators
Life Length SL
Investigators
Layout table for investigator information
Principal Investigator: Maria José Requena University Hospital Reina Sofía

Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Life Length SL
ClinicalTrials.gov Identifier: NCT04124900     History of Changes
Other Study ID Numbers: PROSTAV001
First Posted: October 14, 2019    Key Record Dates
Last Update Posted: October 30, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Life Length SL:
prostate cancer
prostate biopsy
telomere
biomarker
screening
prostate
cancer
biopsy
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases